Asset profile

inavolisib · Pfizer (PFE)

Indication
endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative, advanced breast cancer
Also known as
Itovebi
CompanyPFEPfizer

Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers …

On the calendar

Timeline

Newest first.

Registered trials

Registry IDPhaseStatusPrimary completionEnrollmentSites
NCT07368998Phase 2RecruitingOct 31, 2028804 of 34 sites in the United States
NCT07245797Phase 2Not yet recruitingDec 15, 2026164
NCT07441512Phase 2Not yet recruitingMar 15, 202826
NCT05862285Phase 3RecruitingMar 1, 20332000 of 85 sites in the United States
NCT05332561Phase 2RecruitingMar 1, 20302400 of 9 sites in the United States
NCT07748208Phase 2RecruitingJun 15, 20294012 of 13 sites in the United States
NCT07405801Phase 2RecruitingDec 19, 20288011 of 59 sites in the United States
NCT04802759Phase 1/2RecruitingMay 30, 202931612 of 32 sites in the United States
NCT05708235Phase 2Active, not recruitingJun 30, 20289760 of 41 sites in the United States
NCT05646862Phase 3RecruitingNov 13, 202642039 of 210 sites in the United States
NCT07287150Phase 2RecruitingMar 31, 20281007 of 50 sites in the United States
NCT07694973Phase 2Not yet recruitingJun 29, 2028620 of 1 sites in the United States
NCT07522697Phase 2Not yet recruitingMay 1, 2030480 of 1 sites in the United States
NCT04849364Phase 2TerminatedOct 24, 20245213 of 13 sites in the United States
NCT04551521Phase 2CompletedDec 30, 2024720 of 9 sites in the United States
NCT07323576Phase 2WithdrawnMar 1, 20290

More from Pfizer

Other drugs and candidates from the same company tracked in this sector.

atirmociclibHR+/HER2- advanced or metastatic breast canceravutometinib + defactinibrecurrent low-grade serous ovarian cancer (LGSOC)berobenatidechronic weight management and obesity-related comorbiditiesbrentuximab vedotinrelapsed or refractory large B-cell lymphomacasdatifanclear cell renal cell carcinoma (ccRCC)cemsidomiderelapsed/refractory multiple myelomaCOMIRNATY XFGCOVID-19 prevention in adults 65+ and individuals 5-64 with high-risk conditionsdurvalumabmuscle-invasive bladder cancer (MIBC) ineligible for or refusing cisplatin-based chemotherapyelranatamabrelapsed or refractory multiple myeloma (RRMM) who received at least one prior line of treatment with anti-CD38 therapy and lenalidomideenfortumab vedotin-ejfvmuscle-invasive bladder cancer (MIBC) as neoadjuvant and adjuvant treatmentgedatolisibHR+/HER2- locally advanced or metastatic breast cancer without PIK3CA mutation after progression on endocrine therapyinotuzumab ozogamicinrelapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemiain vivo CAR-T programsautoimmune diseasesmarstacimab-hncqhemophilia A or B with inhibitors (ages 12+, ≥35 kg)palbociclibHR+, HER2+ locally advanced or metastatic breast cancer maintenance treatment following inductionpembrolizumablocally advanced or metastatic urothelial cancerPF-07307405Lyme diseasePF-07872412prevention of invasive pneumococcal disease (IPD) in infants and childrenPF-08046031all human diseases and disordersralinepagpulmonary arterial hypertension (PAH)ritlecitinibnonsegmental vitiligosigvotatug vedotinpreviously treated metastatic non-squamous non-small cell lung cancertalazoparibHRR gene-mutated metastatic androgen pathway modulation-naïve or -sensitive prostate cancer (mHSPC)tilrekimigmoderate-to-severe atopic dermatitis
inavolisib · Pfizer (PFE) — FDA Timeline & Readiness Checklist | SimianX AI